MedTrace Logo

Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery

NCT00468429 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-06-04

No results posted yet for this study

Summary

This study analyzes the safety and efficacy of off-label Subconjunctival Injection of bevacizumab (Avastin) versus 0.02% mitomycin C (MMC) for preventing bleb failure following glaucoma filtration surgery.

Conditions

Interventions

DRUG

Subconjunctival Bevacizumab

Sponsors & Collaborators

  • Grewal Eye Institute

    lead OTHER

Principal Investigators

  • Rajeev Jain, MD · Grewal Eye Institute

  • SPS Grewal, MD · Grewal Eye Institute

  • Gagandeep S Brar, MD · Grewal Eye Institute

  • Dilraj S Grewal, MBBS · Grewal Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Completion
2007-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468429 on ClinicalTrials.gov